| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9346108 | Ophthalmology | 2005 | 7 Pages |
Abstract
Subcutaneous daclizumab induction treatments at 2 mg/kg followed by 1 mg/kg maintenance treatments every other week seems safe and, in most cases, may reduce the concomitant immunosuppressive load required to treat noninfectious uveitis for 12 to 26 weeks.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Robert B. MD, Jan S. MS, RAC, C. Stephen (FACS), Narsing A. MD, Robert F. MD, Eric MD, Ronald R. MD,